This post was originally published on this site
https://i-invdn-com.investing.com/trkd-images/LYNXMPEJ1C0YD_L.jpg
Reed, 64, will replace William Hait, who was appointed the interim head of the unit in August 2022.
Reed has previously served in executive positions for drugmakers Sanofi (NASDAQ:SNY) SA and Roche Holding AG (OTC:RHHVF).
